

AMENDMENTS TO THE CLAIMS

1. (Amended) A process which comprises expressing from a recombinant DNA vector in a suitable host organism a polypeptide incorporating one or more antigenic determinants capable of raising HCMV-neutralising antibodies in humans, said determinant or determinants corresponding to a portion of the protein encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary and/or a portion of the protein encoded by DNA in the HindIII L fragment of the HCMV genome lying between 228 and 2456 bases from the L/D boundary.
2. (Amended) A process according to claim 1 ~~in which~~ wherein said polypeptide is incorporated into a vaccine against HCMV in humans.
3. (Amended) A recombinant virus vector containing DNA encoding a polypeptide incorporating one or more antigenic determinants capable of raising HCMV-neutralising antibodies in humans, said determinant or determinants corresponding to a portion of the protein encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary and/or a portion of the protein encoded by DNA in the HindIII L fragment of the HCMV genome lying between 228 and 2456 bases from the L/D boundary, said vector being capable of infecting a human subject and expressing said polypeptide in immunogenic form.
4. (Amended) A vaccine against HCMV, ~~incorporating~~ comprising a recombinant virus vector of claim 3.
5. (Amended) A DNA isolate which encodes a polypeptide incorporating one or more antigenic determinants capable of raising HCMV-neutralising antibodies in humans, said determinant or determinants corresponding to a portion of the protein encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary and/or a portion of the protein encoded by DNA in the HindIII L fragment of the HCMV genome lying between 228 and 2456 bases from the L/D boundary.
6. (Amended) A process which comprises synthesizing a polypeptide incorporating one or more antigenic determinants capable of raising HCMV-neutralising antibodies in humans, said

determinant or determinants corresponding to a portion of the protein encoded b DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary and/or a portion of the protein encoded by DNA in the HindIII L fragment of the HCMV genome lying between 228 and 2456 bases from the L/D boundary.

7. (Amended) A method of preparing HCMV monospecific antiserum, which comprises ~~immunising~~immunizing a host animal with a polypeptide prepared by a process of claim 1 [or claim 6 or with a recombinant virus vector of claim 3], and extracting from the host animal antiserum specific to said polypeptide.
8. (Amended) A method which comprises ~~immunising~~immunizing a host animal with a polypeptide prepared by a process of claim 1 [or claim 6 or with a recombinant virus vector of claim 3], and preparing HCMV-specific monoclonal antibody from cells of the animal thus ~~immunised~~immunized.
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (New) A method of preparing HCMV monospecific antiserum, which comprises immunizing a host animal with a recombinant virus vector of claim 3 and extracting from the host animal antiserum specific to said polypeptide.
13. (New) A method of preparing HCMV monospecific antiserum, which comprises immunizing a host animal with a polypeptide prepared by a process of claim 6 and extracting from the host animal antiserum specific to said polypeptide.
14. (New) A method which comprises immunizing a host animal with a recombinant virus vector of claim 3 and preparing HCMV-specific monoclonal antibody from cells of the animal thus immunized.
15. (New) A method which comprises immunizing a host animal with a polypeptide prepared by the process of claim 6 and preparing HCMV-specific monoclonal antibody from cells of the animal thus immunized.

16. (New) HCMV monospecific antisera prepared by the method of claim 7.
17. (New) HCMV monospecific antisera prepared by the method of claim 12.
18. (New) HCMV monospecific antisera prepared by the method of claim 13.
19. (New) HCMV-specific monoclonal antibodies prepared by the method of claim 8.
20. (New) HCMV-specific monoclonal antibodies prepared by the method of claim 14.
21. (New) HCMV-specific monoclonal antibodies prepared by the method of claim 15.
22. (New) Isolated HCMV antibodies raised against an antigenic determinant of HCMV glycoprotein gH.
23. (New) The antibodies of claim 22, wherein the antibodies are polyclonal antibodies.
24. (New) The antibodies of claim 22, wherein the antibodies are monoclonal antibodies.
25. (New) Isolated HCMV antibodies raised against an antigenic determinant of HCMV glycoprotein gB.
26. (New) The antibodies of claim 25, wherein the antibodies are polyclonal antibodies.
27. (New) The antibodies of claim 25, wherein the antibodies are monoclonal antibodies.
28. (New) Human cytomegalovirus (HCMV) monospecific polyclonal antisera prepared by a method comprising:
 - (a) expressing from a recombinant DNA vector in a suitable host organism an HCMV glycoprotein polypeptide capable of raising HCMV antibodies in humans, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; (ii) an HCMV gH polypeptide from an HCMV strain functionally equivalent to HCVM strain AD169; and (iii) the HCMV glycoprotein of (i) or (ii) lacking the C-terminal membrane anchor sequence;
 - (b) immunizing a host animal with the polypeptide of step (a); and
 - (c) isolating monospecific antiserum from the host animal that is specific to said polypeptide.

29. (New) Human cytomegalovirus (HCMV) monospecific polyclonal antisera prepared by a method comprising:
- (a) providing a recombinant virus vector containing DNA encoding an HCMV glycoprotein polypeptide capable of raising HCMV antibodies in humans, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; (ii) an HCMV gH polypeptide from an HCMV strain functionally equivalent to HCMV strain AD169; and (iii) the HCMV glycoprotein of (i) or (ii) lacking the C-terminal membrane anchor sequence;
 - (b) immunizing a host animal with the recombinant virus vector of step (a); and
 - (c) isolating monospecific antiserum from the host animal that is specific to said polypeptide.
30. (New) Human cytomegalovirus (HCMV) monospecific polyclonal antisera prepared by a method comprising:
- (a) synthesizing an HCMV glycoprotein polypeptide capable of raising HCMV antibodies in humans, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; (ii) an HCMV gH polypeptide from an HCMV strain functionally equivalent to HCMV strain AD 169; and (iii) the HCMV glycoprotein of (i) or (ii) lacking the C-terminal membrane anchor sequence;
 - (b) immunizing a host animal with the polypeptide of step (a); and
 - (c) isolating monospecific antiserum from the host animal that is specific to said polypeptide.
31. (New) HCMV monospecific polyclonal antisera according to claim 28, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5, (ii) an HCMV gH

- polypeptide from an HCMV strain functionally equivalent to HCVM strain AD 169, and (iii) the HCMV gH of (i) or (ii) lacking the C-terminal membrane anchor sequence.
32. (New) HCMV monospecific polyclonal antisera according to claim 29, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5, (ii) an HCMV gH polypeptide from an HCMV strain functionally equivalent to HCVM strain AD 169; and (iii) the HCMV gH of (i) or ii lacking the C-terminal membrane anchor sequence.
33. (New) HCMV monospecific polyclonal antisera according to claim 30, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5, (ii) an HCMV gH polypeptide from an HCMV strain functionally equivalent to HCVM strain AD 169; and (iii) the HCMV gH of (i) or ii lacking the C-terminal membrane anchor sequence.
34. (New) HCMV monospecific polyclonal antisera according to claim 31, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; and (ii) the HCMV gH of (i) lacking the C-terminal membrane anchor sequence.
35. (New) HCMV monospecific polyclonal antisera according to claim 32, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; and (ii) the HCMV gH of (i) lacking the C-terminal membrane anchor sequence.
36. (New) HCMV monospecific polyclonal antisera according to claim 33, wherein said polypeptide is selected from the group consisting of (i) an HCMV glycoprotein H (gH) polypeptide comprising an amino acid sequence as depicted in Figure 5; and (ii) the HCMV gH of (i) lacking the C-terminal membrane anchor sequence.